The multidrug resistance (MDR) among pathogenic bacteria is jeopardizing the worth of 38 antimicrobials, which had previously changed medical sciences. In this study, we used 39 bioinformatic tools to identify the endolysins ElyA1 and ElyA2 (GH108-PG3 family) present in the 40 genome of bacteriophages Ab1051Φ and Ab1052Φ, respectively. The muralytic activity of these 41 endolysins over MDR clinical isolates (Acinetobacter baumannii, Pseudomonas aeruginosa and 42
13 out of 17 strains of K. pneumoniae. No activity was detected when assays were done with 48 endolysin ElyA2. The combined antimicrobial activity of colistin and endolysin ElyA1 yielded a 49 reduction in the colistin MIC for all strains studied, except K. pneumoniae. These results were 50 confirmed in vivo in G. mellonella survival assays. In conclusion, the combination of colistin with 51 new endolysins such as ElyA1 could increase the bactericidal activity and reduce the MIC of the 52 antibiotic, thus also reducing the associated toxicity. 53
IMPORTANCE 54
The development of multiresistance by pathogen bacteria increases the necessity of the 55 development of new antimicrobial strategies. In this work, we combined the effect of the colistin 56 with a new endolysin, ElyA1, from a bacteriophage present in the clinical strain of Acinetobacter 57 baumannii Ab105. ElyA1 is a lysozyme-like family (GH108-GP3), whose antimicrobial activity 58 was described for first time in this work. Also, another endolysin, ElyA2, with the same origin and 59 family, was characterized but in this case no activity was detected. ElyA1 presented lytic activity 60 over a broad spectrum of strains from A. baumannii, Pseudomonas aeruginosa, and Klebsiella 61 pneumoniae. When colistin was combined with ElyA1 an increase of the antimicrobial activity was observed with a reduced concentration of colistin, and this observation was also confirmed in vivo 63
in Galleria mellonella larvae. The combination of colistin with new endolysins as ElyA1 could 64 increase the bactericidal activity and lowering the MIC of the antibiotic, thus also reducing the 65 associated toxicity. The worldwide emergence of multidrug resistant (MDR) microorganisms that are refractory to 90 treatment with current therapeutic agents has emphasised the urgent need for new classes of 91 antimicrobial agents (1) . Recently, the World Health Organization (WHO) published a list of 92 "priority pathogens" which includes those microorganisms that are considered a serious threat to 93 human health and for which new anti-infective treatments are urgently needed. The members of this 94 list are carbapenem-resistant A.baumannii, P.aeruginosa and K.pneumoniae clinical isolates (2). 95
A consequence of the emergence of the MDR bacteria is the return to the use of antimicrobials 96 whose use was reduced or abandoned. This was the case of colistin or polymixin E, a cationic 97 peptide which disturbs the stability of the outer membrane increasing its permeability through 98 electrostatic interactions and cationic displacement of the lipopolysaccharide. In spite of its 99 antimicrobial effects, this antibiotic presented nephrotoxicity effects and finally its use was 100 gradually dismissed and substituted by other more tolerable antibiotics (3, 4). The search of new 101 antimicrobial agents as well as their combination with old antibiotics such as colistin are new 102 strategies in seeking novel treatments against MDR microorganisms. 103
In recent years, a novel drug discovery approach has explored endolysin enzymes (also referred to 104 as enzybiotics) encoded by bacteriophages (viruses which infect bacteria) (5). Endolysins are 105 actively produced during the lytic cycle and exert antibacterial activity through degradation of 106 peptidoglycan in the bacterial cell wall (5, 6). 107
Endolysins are highly evolved enzymes produced by bacteriophages to digest the bacterial cell wall 108 at the end of their replication cycle and release the phage progeny. Endolysins target the integrity of 109 the cell wall and attack one of the major bonds in the peptidoglycan layer. They can be classified 110 into five groups according to the cleavage site: N-acetyl-β-D-muramidase (lysozymes); N-acetyl-β-111 D-glucosaminidases (glycosidases); lytic transglycosylase; N-acetylmuramoyl-L-alanine amidases 112 and L-alanoyl-D-glutamate endopeptidases (6, 7). 113
Endolysins are good candidates as new antimicrobial agents against Gram-positive bacteria, in 114 evaluated the potential use of endolysin against Gram-positive bacteria such as Staphylococcus 116 aureus, Streptococcus agalactiae, Streptococcus pneumoniae and Streptococcus pyogenes in animal 117 models of human infections and diseases (8-16). In Gram-negative bacteria, the outer membrane 118 acts as a barrier to many endolysins, and very few endolysins with exogenous activity against 119
Gram-negative bacteria have been described (many are biotechnologically engineered) (17) (18) (19) (20) . 120
Endolysins can attack Gram-negative bacteria when the outer membrane is previously 121 permeabilized with agents such as EDTA, which destabilizes the lipopolysaccharides of the outer 122 membrane; however, the combination of endolysin and EDTA is limited to a topical treatment of 123 localized infections (21, 22). In the search for alternative methods of killing MDR bacteria such as 124
A. baumannii, P.aeruginosa and K.pneumoniae various researchers have considered increasing the 125 muralytic activity of endolysins by combining them with different antibiotics to take advantage of 126 synergistic responses (22-25). 127
In this report, we identified and characterized an endolysin, named ElyA1, isolated from the 128 A. baumannii Ab105 (ROC0034a) bacteriophage Ab1051Φ. The endolysin displayed muralytic 129 activity against a broad spectrum of MDR organisms. In addition, combining endolysin ElyA1 with 130 colistin (polymyxin E) enhanced the susceptibility of the tested strains to colistin by at least four 131 times, thus highlighting the potential of endolysin ElyA1 as an antibacterial agent candidate. This 132 effect was confirmed by a test in vivo, in which the survival of the G. mellonella larvae increased 133 when colistin (¼ MIC) was supplemented with endolysin ElyA1. Moreover, another endolysin from 134 the same family, named ElyA2, was identified in the A. baumannii Ab105 bacteriophage Ab1052Φ, 135 but no muralytic activity was detected in this enzyme. 136
MATERIALS AND METHODS 137

Strains and culture conditions 138
The bacterial strains and plasmids used in this study included 25 A. baumannii MDR strains 139 belonging to 22 different sequence types (STs) ( Table 1 ). The strains were isolated from colonized the participation of 45 Spanish hospitals (GEIH-REIPI Acinetobacter baumannii [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] 142 Genbank Umbrella Bioproject accession number PRJNA422585)(26). They included 25 MDR 143 clinical strains of P. aeruginosa (many included in CC274), all of which were isolated from cystic 144 fibrosis patients, and 17 carbapenemase-producing strains of K. pneumoniae, which were isolated in 145 20 Spanish hospitals during the EuSCAPE project (27, 28). Moreover, Escherichia coli DH5α and 146
Rosetta strains were used in cloning assays ( Table 1) . 147
All strains were cultured in LB (Luria Bertani) at 180 rpm and 37ºC. For solid medium, 2% of agar 148 was added to LB broth. When transformation assays were done the medium was supplemented with 149 50µg/ml of ampicillin. 150
Identification and Purification of the endolysins ElyA1 and ElyA2 151
Endolysin gene prediction, from the genome of the bacteriophage Ab105Φ1 (GenBank: 152 KT588074.1) and Ab105Φ2 (GenBank: KT588075.2) (26) (Figure 1 InterProScan and the domain graphic was assigned with PROSITE MyDomains. 157
The endolysin genes were amplified by PCR from the genomic DNA of A. baumannii Ab105, 158 which contains the DNA of the prophages Ab105Φ1 and Ab105Φ2, and cloned into the expression 159 vector pET-28a (Novagen). The recombinant plasmids were transformed into competent E. coli 160 DH5α cells (Novagen) for DNA production and purification, and the integrity of both constructs 161 was verified by sequencing. All of the primers used are listed in Table 1 . Finally, the plasmids were 162 transformed into Escherichia coli Rosetta pLys-S cells (Novagen) for expression of the protein. equilibrated with 150 mM NaCl, 20 mM Tris pH 7.5 and 1 mM TCEP. The protein was eluted in a 173 single peak. Finally, the pooled peak fractions were concentrated to 40 mg/ml, as previously 174 described. The purification process was carried out at 4º C, and the purity was determined by SDS-175 PAGE ( Figure 1 ). 176
Determination of the muralytic activity of endolysins ElyA1 and ElyA2 177
Muralytic activity was determined using the Gram-negative overlay method described by Schmitz 178 et al (29). Briefly, two clinical isolates of A. baumannii, MAR001 and PAU002, were grown to 179 stationary phase (10 9 CFU/ml) in LB, pelleted and resuspended in PBS buffer pH 7.4. Agar was 180 added directly to the bacteria suspension suspension at a concentration of 0.8% and autoclaved for 181 15min at 120ºC. The medium, containing the disorganized cells with the peptidoglycan exposed, 182 was solidified in Petri dishes and aliquots (50 µg) of endolysin, or the endolysin buffer as negative 183 control were spotted on the surface. 184
The muralytic activity was measured using as target a culture of A. baumannii Ab105 treated with 185 EDTA in order to permeabilize the outer membrane. An overnight culture of A. baumannii Ab105 186 was diluted 1:100 in LB medium and grown to exponential phase (0.3-0.4 OD600nm). The culture 187 was centrifuged (3000g, 10min), and the resulting pellet was resuspended in 20mM Tris-HCl buffer 188 at pH 8.5 with 0.5 mM EDTA before being incubated for 30 min at room temperature. The pellet 189 was recovered by centrifugation and washed twice in Tris-HCl buffer pH 8.5. Finally, the cells were 190 resuspended in 20 mM Tris-HCl 150 mM NaCl pH8.5 and 25 µg/ml of endolysin ElyA1. The 191 activity was measured by the turbidity reduction assay, as a decrease in the OD600nm after minutes for a period of 20 minutes and the time point of the higher activity was established. Also, 194 the optimal pH and temperature for the endolysin activity were determined employing the turbidity 195 reduction assay. The reaction was done as described previously, with the Tris-HCl at different pH 196 (range 6.5 to 9) and temperature (room temperature, 30ºC and 37ºC). 197
Antibacterial assays 198
The antibacterial activity of the endolysin was assayed with all of the 67 clinical strains of A. 199 baumannii, P. aeruginosa and K. pneumoniae ( Table 1 ). The activity was determined using the 200 turbidity reduction assay, as previously described, at pH 8.5 and 37ºC. The incubation times in the 201 presence of EDTA varied according to the species assayed: 30 min for A. baumannii and K. 202 pneumoniae and 15 min for P. pneumoniae. 203
Broth microdilution checkerboard assay and microdilution test to determine minimum 204 inhibitory concentrations (MICs) 205
This assay was done in those strains with the higher and the lower susceptibility to endolysin. All 206 the strains tested were susceptible to colistin except three strains that were colistin resistant: A. 207 baumannii SOF004b, P. aeruginosa AUS034 and K. pneumoniae KP2. The effect of the interaction 208 between endolysin and colistin was done by the chequerboard MIC assay. In a 96-well microtiter 209 plate with Mueller-Hinton Broth (MHB), 7 serially double dilutions were done for endolysin and 6 210 for colistin. The wells were then inoculated with the test culture at a final concentration of 10 5 211 colony forming units (cfu/ml). The MIC of colistin (0 to 2 µgml -1 ) and concentration of endolysin 212 Time kill curve assays were carried out with those strains in which the MIC of colistin in ElyA1-220 colistin combinations was decreased by at least fourfold in checkerboard assays. The assay was 221 conducted according to previously described techniques (30). Flasks of LB containing colistin and 222 colistin plus endolysin at the concentration corresponding to the checkerboard assay were 223 inoculated with a dilution 1:100 of an overnight culture in stationary phase of the tested strain and 224 incubated at 37ºC and 180 rpm in a shaking incubator. Aliquots were removed after 0, 6 and 24 h 225 and were serially diluted and plated to produce colony forming units (cfu). Synergy was established 226 when a ≤2 -log 10 decrease in cells counts at 6 or 24 h in the antimicrobial combination relative to the 227 most active single agent was observed. No effect was considered to have occurred when the counts 228 were <2-log 10 lower or higher relative to the culture with the single agent. Antagonism was defined 229 when the counts in the culture with antimicrobial combination were ≥ 2-log 10 higher than in the 230 culture with single most active antimicrobial agent. 231
The reduction in the MIC of the colistin in combination with endolysins was also assayed by 232 combining colistin with another endolysin ElyA2, isolated from the bacteriophage Ab105Φ2. The 233 curve was done for the same strains and under the same conditions as for colistin-ElyA1. 234 As ElyA1 protein, this enzyme presented a high homology (more than 80%) with the same group of 264 9 endolysins and also a homology of 90% with ElyA1 protein (20). 265
Galleria mellonella Infection Model
Endolysins muralytic activity characterization 266
In the first screening of the muralytic activity of the purified endolysin ElyA1 in the Gram-negative 267 overlay plates, a lysis halo appeared in both strains of A. baumannii tested (Figure 2a ). 268
The muralytic activity of this enzyme was characterized using the Gram-negative bacteria A. 269
baumannii Ab105 as substrate, as this is the host strain for the phage Ab105Φ1. The enzymatic 270 activity was obtained after incubation for 10 min at pH8.5 and 37ºC (Figure 2b-c) . In addition, the 272 muralytic activity on the cells of Ab105 was assayed directly or after treatment of the cells with 273 EDTA to permeabilize the outer membrane. However, no activity was detected when the enzyme 274 was added directly to the cells whose outer membrane was not previously permeabilized with 275 EDTA, and also in this case the cells tended to aggregate (data not shown). 276
The antibacterial assays showed a broad lytic spectrum of activity against the strains of the three 277 species tested ( Figure 3 ). As expected because of the origin of the A. baumannii endolysin, the 278 highest activity observed was among the 25 A. baumannii strains tested. Although the activity was 279 more variable in P. aeruginosa, muralytic activity was detected against all of the strains tested. 280
Finally, endolysin ElyA1 displayed activity against 13 of the 17 K. pneumoniae strains, although at 281 lower levels than in A. baumannii and P. aeruginosa. The strains tested in the three species 282 belonged to different STs, but no correlation between the susceptibility to endolysin ElyA1 and the 283
ST was detected. 284
When muralytic activity of endolysin ElyA2 was tested no activity was detected under any 285 condition assayed. On the contrary, this enzyme induces the aggregation of the cells at all the 286 enzyme concentration tested both in those cells treated previously with EDTA and in those with an 287 intact outer membrane. 288
Endolysin ElyA1 and colistin combination activity Assays 289
As endolysin ElyA1 is only active when the outer membrane of the target bacterial cell is 290 solubilized, the MIC of the endolysin was not able to be determined by the microdilution 291 checkerboard test. We therefore aimed to detect any decrease in the colistin MICs when used in 292 combination with endolysin ElyA1. The addition of endolysin ElyA1 yielded a fourfold reduction 293 in the colistin MICs in four of the six strains tested (A. baumannii GMA001 and PON001, P. 294 aeruginosa AUS531 and K. pneumoniae KP17) (Figure 4) . By contrast, only a twofold reduction in 295 the colistin MIC was observed with P. aeruginosa AUS601 and no decrease with K. pneumoniae 296 assays ( Figure 4 ). Finally, no antimicrobial activity was detected when the combination was tested 298 in the colistin resistant isolates (data not shown). 299
The results of the time kill curve assay confirmed the results obtained by the microdilution 300 checkerboard test (Figure 4) . A 2 log reduction was shown in the growth of both the A. baumannii 301 strains and P. aeruginosa AUS531 after 6 hours in the culture with 1/4 of colistin and endolysin 302 ElyA1, indicating a synergetic reaction between colistin and endolysin ElyA1. By contrast, no 303 reduction was observed in the K. pneumoniae KP17 culture. 304
Mortality in the in vivo Galleria mellonella Model 305
Larvae of the wax moth were infected with the clinical strain of A. baumannii PON001. When 306 infected larvae were treated with colistin (¼MIC) in combination with endolysin ElyA1 (25 µg/ml), 307 a significative increase (P<0.05) in the survival was observed in the treated larvae respect to those 308 treated only with colistin (¼ MIC) (Figure 5a ). When colistin (¼ MIC) was combined with ElyA2 309 (25 µg/ml) no significative differences (P>0.05) were obtained when compared with the treatment 310 with colistin, as no muralytic activity was previously detected with ElyA2 (Figure 5b) . 311
DISCUSSION 312
The discovery and development of novel antimicrobial agents to treat infections caused by the 313 "priority" group of pathogens has occurred in the medical and research community (2). 314
Enzybiotics have become a focus of attention of many research groups worldwide. Endolysins, one 315 type of enzybiotic, are species or genus-specific enzymes that act by hydrolysing the peptidoglycan 316 layer of the bacterial cell wall. There are no reports of bacteria developing resistance to endolysins, 317 which is a great problem in both antibiotic therapy and also in phage therapy (16). Moreover, 318 endolysins have been recognized by the United States of America in the National Action Plan for 319
Combating Antibiotic-resistant Bacteria (33), which identified the use of "phage-derived lysins to 320 kill specific bacteria while preserving the microbiota" as a key strategy to reduce the development 321 of antimicrobial resistance (34) due to the absence of toxicity in human cells (35) . 322 endolysins to their natural target, the peptidoglycan layer. This problem has been approached by 324 different strategies, including solubilization of the outer membrane with EDTA, modification of the 325 endolysin PGs by deletion or substitution and by the development of fusion proteins such Artilysin-326 175, made by fusing the endolysin with a peptide to enable the enzyme to pass through the outer 327 membrane which has been a successful strategy (18, 36, 37). In P.aeruginosa strains, Briers et al. 328 (18) worked in the development of Art-175 constituted by antimicrobial peptide (AMP) sheep 329 myeloid 29-amino acid peptide (SMAP-29) fused with endolysin KZ144. Art-175 showed 330 muralytic activity in P.aeruginosa isolate and continuous exposure to Art-175 did not elicit the 331 development of resistance. On its own, SMAP-29 is cytotoxic to mammalian cells (38); however, 332
Art-175 exhibited little toxicity in L-292 mouse connective tissue. 333
As a new strategy we combined the membrane destabilizing effect of the colistin ("last-line" 334 treatment for these bacteria due to the concerns about its nephrotoxicity and neurotoxicity (39)), 335 which is a cationic peptide used as an active outer membrane agent, and two endolysins identified 336 by our research group that belong to a lysozyme-like family (GH108-PG3) never before used as 337 antimicrobial treatment. 338
In this work we identified two endolysins, ElyA1 and ElyA2, obtained from A. baumannii domain has been shown to be responsible for the specificity and affinity of the endolysins for its 354 substrate (43). However, we observed that endolysin ElyA1 displays a broader spectrum of activity 355 against strains of A. baumannii and also many strains of P. aeruginosa belonging to the same order, 356
Pseudomonadales, and to lesser extent some strains of K. pneumoniae from another 357 gammaproteobacterial order, Enterobacteriales. In this case, the target of endolysin ElyA1, 358 identified in Peptidoglycan binding domains (PGs) as a D-Asn (43), is probably conserved among 359 the Pseudomonadales, thus explaining the broad spectrum of action of this enzyme. Interestingly, 360
we were not able to detect muralytic activity in endolysin ElyA2 because this enzyme induces the 361 aggregation of the cells in vitro, probably preventing the activity of the enzyme over all the cells. 362
In the present study, we used the cationic polymyxin antibiotic colistin to overcome the 363 impenetrability of the outer membrane to endolysin ElyA1. Colistin disturbs the outer membrane 364 via an electrostatic interaction with lipopolysaccharides and phospholipids present in the outer 365 membrane (4). The synergistic effect of endolysin LysABP-01 (Lysozyme-like protein from the 366 GH19 family) and colistin on A. baumannii has previously been described (25). Although endolysin 367 ElyA1 does not display exogenous activity, because of its inability to cross the outer membrane, 368 this problem was largely overcome when the enzyme was used in combination with colistin, and the 369 antimicrobial activity of the combined therapy was higher than for both substances used alone in all 370 the tested strains except for those of K. pneumoniae. A reduction in the colistin MIC of at least 371 fourfold occurred for all of the A. baumannii strains tested and for P. aeruginosa strain AUS531, 372 and a corresponding twofold reduction was observed for P. aeruginosa strain AUS601. A reduction 373 in the colistin MIC was also obtained for the K. pneumoniae strain KP17, the most susceptible to 374 confirmed with the almost 3 log reduction in growth after 6 h in all strains tested, except KP17 K. 376 pneumoniae. Growth of the culture reached the same level as in the control after 24 h, probably due 377 to degradation of the enzyme and colistin, as also reported by Thummeepak et al. (22) . In all of the 378 strains tested the reduction in the colistin MIC was consistent with the muralytic activity of 379 endolysin ElyA1 obtained for those strains. No antimicrobial activity was observed when this assay 380 was conducted in colistin-resistant strains, probably because of the inability of the enzyme to access 381 the peptidoglycan layer, as the necessary destabilization of the outer membrane by the colistin was 382 not produced in these isolates. However, there are several resistance mechanisms to colistin 383 described which include those in which the lipopolysaccharide is modified or is not produced 384 preventing the joint of the colistin to the outer membrane, but there are other mechanisms in the 385 literature which include efflux pumps described in A. baumannii and inhibition of respiratory 386 enzymes as NADH oxidase in Gram positives as Bacillus spp and NADH quinone oxidoreductase 387 in E. coli. It is probable that the activity of the enzyme would be higher in the bacteria with colistin 388 resistance mechanisms different from that who modify the lipopolysaccharides (45-51). Future 389 studies will be done over a range of different colistin resistant bacteria in order to reduce the MIC 390 for colistin in combination with endolysin ElyA1. 391
The results obtained in vitro were confirmed with the assays done in vivo, as the survival of the 392 infected larvae of G. mellonella was higher when the worms were treated with a combination of a 393 reduced fourfold MIC of colistin and endolysin ElyA1 than with colistin alone. As a control the 394 same assay was performed with endolysin ElyA2, in which the muralytic activity was not detected, 395 and no differences were observed with the treatment with colistin. 396
In conclusion, this is the first study in vitro and in vivo (G.mellonella) where colistin is 397 combined with endolysin ElyA1 (Glycosyde hydrolase 108 superfamily) against clinical MDR 398 pathogens, which may enable the concentration of colistin used in antimicrobial treatments to be 399 reduced, thus also reducing the toxic side effects of the antibiotic. The broad spectrum of action of 400 endolysin ElyA1 would enable more MDR Gram-negative bacteria to be included as targets for this 401 combined antimicrobial treatment. 
